Although significant progress has been made in understanding vitiligo, managing the condition remains a challenge. Many treatments can achieve noticeable repigmentation (over 75%) on areas like the face and neck. However, nearly 40% of patients experience a relapse within the first year after stopping treatment.

Pierre Fabre Laboratories are testing their topical product, RV5098A, designed specifically for people with vitiligo. They believe it could help maintain pigmentation in areas that have already been successfully repigmented, especially for adults with facial vitiligo.

Participants will be recruited through the investigator’s outpatient clinic or the center’s database. Those who meet the basic eligibility criteria may be contacted via phone, email, or letter to discuss joining the study.

For a detailed list of eligibility criteria, interested individuals are encouraged to contact the study team or visit the trial’s official page. Only the research staff can confirm if someone is fully eligible to participate.